Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of DC-CIK (Dendritic Cell-Cytokine-Induced Killer) cells in preparation of medicine used for resisting HIV (Human Immunodeficiency Virus) infection

A technology of drugs and cytokines, applied in the field of biomedicine

Inactive Publication Date: 2012-06-27
JIANGSU PROVINCIAL CENT FOR DISEASE PREVENTION & CONTROL
View PDF5 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

CIK cells are also used in the treatment of viral diseases of hepatitis B [13，14] , but there is no relevant report on the application of adoptive immunotherapy of DC-CIK cells to anti-HIV virus therapy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of DC-CIK (Dendritic Cell-Cytokine-Induced Killer) cells in preparation of medicine used for resisting HIV (Human Immunodeficiency Virus) infection
  • Application of DC-CIK (Dendritic Cell-Cytokine-Induced Killer) cells in preparation of medicine used for resisting HIV (Human Immunodeficiency Virus) infection
  • Application of DC-CIK (Dendritic Cell-Cytokine-Induced Killer) cells in preparation of medicine used for resisting HIV (Human Immunodeficiency Virus) infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1HI

[0026] Example 1 Detection of DC and CIK cell content and function in HIV-infected persons / AIDS patients

[0027] 1. Materials: Take 10ml of peripheral blood from HIV-negative patients, HIV-infected patients and AIDS patients transmitted by different ways, anticoagulate with EDTA-2K (BD Vacutainer USA), and use 1×PBS phosphate buffer saline (Invitrogen, USA) 1: 1 dilution, and then slowly add the diluted blood to the top of the lymphocyte separation medium (GE Healthcare, Sweden), centrifuge at 1500rpm for 30 minutes to separate peripheral blood lymphocytes (PBMC), wash 2 times with 1×PBS, and prepare for the following analysis .

[0028] 2. Detection of the content of DC and CIK cells in peripheral blood: take the above separated and washed PBMCs, and the total number of cells is 106. Dilute to 100 μl with 1×PBS. DC cells were labeled with PE-Cy5.5-HLA-DR (Pharmingen USA), APC-CD11c (Pharmingen) and PE-CD123 (Pharmingen). CD11c+CD123+ positive cells were defined as DC cells...

Embodiment 2

[0033] Example 2 Preparation and reinfusion of autologous DC-CIK cells

[0034] 1. Preparation of DC and CIK cells: Use a blood cell separator to collect peripheral blood PBMCs from patients. After removing plasma, separating, washing and counting, respectively culture DC and CIK cells according to the method in Example 1, and culture them for 6 days DC and CIK cells were co-cultured for 3 days. The separation and other operations after cell collection should be performed in a sterile laboratory, and each link must be operated in strict accordance with the aseptic rules, and a sterility test should be performed on each batch of cells to ensure that the cells are not contaminated.

[0035] 2. Reinfusion of DC and CIK cells: collect the co-cultured DC and CIK cells, and digest the DC cells with 0.25% trypsin for 5 minutes before collecting them. The collected DC and CIK cells were washed 3 times with serum-free 1640 medium. Immediately after collection, the DC cells were subcu...

Embodiment 3

[0036] Example 3 Observation of curative effect of patients after autologous cell reinfusion

[0037] 1. Follow-up of patients after reinfusion of autologous cells: medical follow-up of patients was carried out on days 0, 3, 5, 10, 30, 60, 90, 120, 240 and 360 after reinfusion of cells. The main content of the follow-up visit is: the follow-up visit on days 0-10 is mainly to understand the side effects of the patient after the reinfusion of cells. During the follow-up visit, 10ml of blood is collected from the patient and anticoagulated with EDTA. The following medical follow-up is mainly to observe the curative effect after the reinfusion of cells, and to understand the relevant information of the patient after the reinfusion of cell therapy, such as whether there are related opportunistic infections, whether there is high-risk sexual behavior, etc. At the same time, 10ml of blood is collected from the patient. EDTA anticoagulation. The anticoagulated blood collected above n...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of biomedicine and discloses application of DC-CIK cells in preparation of a medicine used for resisting HIV infection. Through a lot of experiments, the inventor discovers that when CIK cells impacted by HIV and DC cells are co-cultured, the CIK cells can obviously promote maturation of the DC cells. When the DC and CIK cells are combined for use, the DC and CIK cells have mutual promotion presentation and a function for killing cells infected by HIV. After 30 days of the DC-CIK cell infusion, the number of CD4T cells of a HIV infector is obviously increased, the killing function of NK (Natural Killer) and CIK cells is enhanced, and HIV viral load is obviously restrained. Thus, kill cells induced by co-cultured dendritic cells and cytokines can be applied to the preparation of the medicine used for resisting HIV infection.

Description

technical field [0001] The invention belongs to the field of biomedicine and relates to the application of DC-CIK cells in the preparation of anti-HIV infection drugs. Background technique [0002] AIDS (acquired immune deficiency syndrome, AIDS) is a chronic infectious disease caused by human immunodeficiency virus (human immunodeficiency virus, HIV). AIDS is clinically divided into three phases: HIV infection period, AIDS-related syndrome period and AIDS period. According to the 2009 Global AIDS Epidemic Trend Report jointly released by UNAIDS and the World Health Organization, there are currently about 33.4 million HIV-infected people in the world, of which 2.7 million were newly infected last year, and 2 million people died of AIDS-related diseases . Of the 15 million AIDS patients who require life-long treatment, only one-third are receiving treatment. The number of new infections still exceeds the number of people starting treatment. In the 2011-2015 strategic goal...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/12A61P31/18
Inventor 傅更锋羊海涛还锡萍徐晓琴胡海洋李雷徐金水邱涛王小亮丁萍刘晓燕陈国红丁建平冯晓英郭宏雄闫红静
Owner JIANGSU PROVINCIAL CENT FOR DISEASE PREVENTION & CONTROL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com